Evidence map›Paper›PMID 33386814›Full record

ArticleJournal of Parkinson's disease2021

Psychometric Properties of the Clinical Dementia Rating Scale Sum of Boxes in Parkinson's Disease.

Julia Gallagher, Jacqueline Rick, Sharon X Xie, Pablo Martinez-Martin, Eugenia Mamikonyan, Alice Chen-Plotkin, Nabila Dahodwala, James Morley, John E Duda, John Q Trojanowski and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of Parkinson's disease, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.5field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Julia GallagherDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Jacqueline RickDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Sharon X XieDepartment of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Pablo Martinez-MartinCenter for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED), Carlos III Institute of Health, Madrid, Spain.
Eugenia MamikonyanDepartment of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Alice Chen-PlotkinDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Nabila DahodwalaDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
James MorleyParkinson's Disease Research, Education and Clinical Center (PADRECC), Philadelphia Veteran's Affairs Medical Center, Philadelphia, PA, USA.
John E DudaDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
John Q TrojanowskiDepartment of Pathology and Laboratory Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Andrew SiderowfDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
Daniel WeintraubDepartment of Neurology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
University of Pennsylvania · USVeterans Health Administration · USCalifornia University of Pennsylvania · USInstituto de Salud Carlos III · ES

Funding

UPenn ADCC Biomarker CoreP30AG010124 · NIA · UNIVERSITY OF PENNSYLVANIA · PI XIE, SHARON XIANGWEN · 1991 to 2020
$35.1M
Project IV: "Alpha-Synuclein Strains & Diverse Synucleinopathies"P50NS053488 · NINDS · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2007 to 2017
$20.9M
Project IV "Tackling Heterogeneity of Cognitive Trajectory in LBD"U19AG062418 · NIA · UNIVERSITY OF PENNSYLVANIA · PI TROJANOWSKI, JOHN Q. · 2019 to 2023
$18.1M
NIA NIH HHS P30 AG010124NIA NIH HHS U19 AG062418NINDS NIH HHS P50 NS053488
6 · The paper itself

Abstract

backgroundA composite measure that assesses both cognitive and functional abilities in Parkinson's disease (PD) would be useful for diagnosing mild cognitive impairment (MCI) and PD dementia (PDD) and as an outcome measure in randomized controlled trials. The Clinical Dementia Rating Scale Sum of Boxes (CDR-SOB) was designed to assess both cognition and basic-instrumental activities of daily living in Alzheimer's disease but has not yet been validated in PD.

objectiveTo validate the CDR-SOB as a composite cognitive-functional measure for PD patients, as well as to assess its sensitivity to change.

methodsThe CDR-SOB and a comprehensive cognitive and functional battery was administered to 101 PD patients at baseline (39 normal cognition [NC], 41 MCI and 21 PDD by expert consensus panel), and re-administered to 64 patients after 1-2 years follow-up (32 NC and 32 cognitive impairment [CI] at baseline).

resultsCross-sectionally, CDR-SOB and domain scores were correlated with corresponding neuropsychological or functional measures and were significantly different between cognitive subgroups both at baseline and at follow-up. In addition, CDR-SOB ROC curves distinguished between normal cognition and dementia with high sensitivity, but did not distinguish well between NC and MCI. Longitudinal changes in the CDR-SOB and domain scores were not significant and were inconsistent in predicting change in commonly-used cognitive and functional tests.

conclusionThe CDR-SOB detects dementia-level cognitive impairment in PD but may not be appropriate for predicting longitudinal combined cognitive-functional changes in patients without significant cognitive impairment at baseline.

Indexed as

Alzheimer DiseaseCognitive DysfunctionParkinson DiseaseActivities of Daily LivingHumansMental Status and Dementia TestsNeuropsychological TestsPsychometricsCognitiondementiaParkinson’s diseaserating scale

Identifiers

PMID33386814
PMCPMC8058172
OpenAlexW3114809859

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.